Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder

Wyeth

Status and phase: Completed; Phase 3

Conditions: Social Anxiety Disorder

Treatments: Drug: Venlafaxine ER

Study type: Interventional

Funder types: Industry

Identifiers

NCT00238719

0600B4-389

Details and patient eligibility

About

To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.

Sex: All

Ages: 8 to 17 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female outpatient
• 8-17 year old
• diagnosis of Social Anxiety Disorder

Exclusion criteria

• concomitant psychiatric or medical disorders which interfere with safety or assessment

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind